drugset / Trial / NCT01167088

A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)

NCT01167088

Phase 2 Terminated 110 enrolled Antipodean Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate whether a new medicine, called mitoquinone, will reduce raised liver enzymes due to NAFLD and to see if it is safe.

Timeline

Start
2010-11
Primary completion
2011-06
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MitoQ Small molecule 40 mg Oral

Indications